Skip to Content

Cigna Corp - Stock Quote CI

Rating as of

Morningstar's Cigna Corp Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Cigna Turns in Strong 1Q on Commercial Membership Expansion; Shares Undervalued

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Cigna turned in better-than-anticipated operating results for the first quarter that allowed management to boost its 2022 outlook a bit. Our bottom-line estimates were already above Cigna's previous guidance, but considering recently generated cash flows and a mild increase in our 2022 expectations, we are raising our fair value estimate 6%. Shares continue to look moderately undervalued to us.

Read Full Analysis

Cigna Corp's Company Profile

Business Description

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.

Contact
900 Cottage Grove Road
Bloomfield, CT, 06002
T +1 860 226-6000
Sector Healthcare
Industry Healthcare Plans
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 73,700

Cigna Corp's Related News